Ipilimumab-induced colitis in patients with metastatic melanoma

Melanoma Research

Volumn 25, Issue 4, 2015, Pages 321-327

  De Felice, Kara M ^a   Gupta, Arjun ^a   Rakshit, Sagar ^a   Khanna, Sahil ^a   Kottschade, Lisa A ^b   Finnes, Heidi D ^b   Papadakis, Konstantinos A ^a   Loftus, Edward V ^a   Raffals, Laura E ^a   Markovic, Svetomir N ^b  

^a Department of Medicine Division of Gastroenterology and Hepatology Bioinformatics Bldg   (United States)

^b MAYO CLINIC   (United States)

Author keywords

budesonide; corticosteroids; immune related adverse events; infliximab

Indexed keywords

ANTIBIOTIC AGENT; BUDESONIDE; INFLIXIMAB; IPILIMUMAB; LOPERAMIDE; METHYLPREDNISOLONE; PREDNISONE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CAMPYLOBACTER JEJUNI; COLITIS; COLON RESECTION; DIARRHEA; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; OBSERVATIONAL STUDY; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; CHEMICALLY INDUCED; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BUDESONIDE; COLITIS; DIARRHEA; FEMALE; HUMANS; INFLIXIMAB; MALE; MELANOMA; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 84936936976     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000165     Document Type: Article

References (17)

1. Tarhini A. Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) 2013; 2013:857519.
2. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007; 110:2614-2627.
3. Nancey S, Boschetti G, Cotte E, Ruel K, Almeras T, Chauvenet M, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3+ regulatory T cells: a mechanistic explanation for ipilimumab-induced severe enterocolitis? Inflamm Bowel Dis 2012; 18:E1598-E1600.
4. HodiF, O'Day S, McDermott D, Weber R, Sosman J, Haanen J, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
5. Ibrahim RBD, Berman DM, DePril V, Humphrey RW, Chen T, Messina M, et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma [abstract]. J Clin Oncol 2011; 29:8583.
6. YERVOY (ipilimumab): serious and fatal immune-mediated adverse reactions. Ipilimumab US prescribing information: risk evaluation and mitigation strategy (REMS) B-MS, 2012. Available at: https://www.hcp. yervoy.com/pdf/rems-management-guide.pdf [Accessed October 2014].
7. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24:2283-2289.
8. Kim KW, Ramaiya NH, Krajewski KM, Shinagare AB, Howard SA, Jagannathan JP, Ibrahim N. Ipilimumab-associated colitis: CT findings. Am J Roentgenol 2013; 200:W468-W474.
9. Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010; 10:11.
10. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13 (Pt 1):6681-6688.
11. Harmankaya K, Erasim C, Koelblinger C, Ibrahim R, Hoos A, Pehamberger H, et al. Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol 2011; 28:1140-1144.
12. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the treat registry. Am J Gastroenterol 2012; 107:1409-1422.
13. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30:2691-2697.
14. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009; 15:5591-5598.
15. Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm 2009; 24:321-325.
16. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012; 143:390.e1-399.e1.
17. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23:6043-6053.